iBio plans to use the offering's net proceeds for general co...
iBio plans to use the offering's net proceeds for general corporate purposes, including R&D and working capital. The funds are expected to extend the company's cash runway through 2025. CEO Martin Brenner thanked healthcare specialist investors for their support.
![](https://pubimg-10000538.picsh.myqcloud.com/20220509000002709197f8a706d.jpg)
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment